Key facts
- This page summarizes Ole Isacson's Form 4 filing for Cyclerion Therapeutics, Inc. (CYCN).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 16 Jun 2022, 20:55.
Ole Isacson - 14 Jun 2022 Form 4 Insider Report for Cyclerion Therapeutics, Inc. (CYCN)
- Reporting relationship
- Director
- Issuer ticker
- CYCN
- Reported as of
- 14 Jun 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 16 Jun 2022, 20:55:57 UTC
- Prior SEC filing
- 28 Jun 2021
- Source filing
- View source filing
- Reporting owner signature
- /s/ Gary J. Simon, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Ole Isacson filed Form 4 for Cyclerion Therapeutics, Inc. (CYCN) on 16 Jun 2022.
Change
- Previous filing in this sequence was filed on 28 Jun 2021.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CYCN
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +20,000
- Change %
- Price
- $0.000000
- Shares after
- 20,000
- Date
- 14 Jun 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 20,000
- Exercise price
- $0.5300
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The options, granted pursuant to the director compensation plan, will vest in full on the first anniversary of the grant date.